Screener
Wave Life Sciences WVE Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of operating lease liability | 3,508 | 8,361 |
| Total current liabilities | 50,815 | 95,065 |
| Long-term liabilities: | ||
| Deferred revenue, net of current portion | 13,904 | 7,798 |
| Operating lease liability, net of current portion | 40,082 | 9,405 |
| Total long-term liabilities | 53,986 | 17,203 |
| Total liabilities | $104,801 | $112,268 |
| Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | $7,874 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's contract liabilities?
- Wave Life Sciences (WVE) reported contract liabilities of $13.9M in Q2 2026.
- How has Wave Life Sciences's contract liabilities changed year-over-year?
- Wave Life Sciences's contract liabilities increased by 228.5% year-over-year, from $4.23M to $13.9M.
- What is the long-term trend for Wave Life Sciences's contract liabilities?
- Over 5 years (2020 to 2025), Wave Life Sciences's contract liabilities has grown at a -28.4% compound annual growth rate (CAGR), from $41.48M to $7.8M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Wave Life Sciences's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude